BIOCRYST PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$13.03 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-08
- BIOCRYST PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$25.91M, a 406.88% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $12.88M, a 375.84% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$9.76M.
- BIOCRYST PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $21.95M.
- BIOCRYST PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $23.34M.
- BIOCRYST PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$18.00M.
- BIOCRYST PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$39.98M.
- BIOCRYST PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$3.47M, a 113.93% decline from fiscal 2012.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$25.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$13.03M 10-Q · filed 2017-08-08 | -$22.79M derived: sum of 3 quarters · filed 2017-08-08 | -$844.00K derived: sum of 4 quarters · filed 2017-08-08 |
| 2017-03-31 | $12.88M 10-Q · filed 2017-05-08 | $3.12M derived: sum of 2 quarters · filed 2017-05-08 | $25.07M derived: sum of 3 quarters · filed 2017-05-08 | $33.51M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-12-31 | -$9.76M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $12.19M derived: sum of 2 quarters · filed 2017-02-27 | $20.63M derived: sum of 3 quarters · filed 2017-08-08 | $23.34M 10-K · filed 2017-02-27 |
| 2016-09-30 | $21.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $30.39M derived: sum of 2 quarters · filed 2017-08-08 | $33.10M 10-Q · filed 2016-11-08 | $30.11M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-06-30 | $8.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $11.15M 10-Q · filed 2017-08-08 | $8.16M derived: sum of 3 quarters · filed 2017-08-08 | -$9.98M derived: sum of 4 quarters · filed 2017-08-08 |
| 2016-03-31 | $2.71M 10-Q · filed 2017-05-08 | -$280.00K derived: sum of 2 quarters · filed 2017-05-08 | -$18.42M derived: sum of 3 quarters · filed 2017-05-08 | -$11.35M derived: sum of 4 quarters · filed 2017-05-08 |
| 2015-12-31 | -$2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$21.13M derived: sum of 2 quarters · filed 2017-02-27 | -$14.06M derived: sum of 3 quarters · filed 2017-02-27 | -$18.00M 10-K · filed 2017-02-27 |
| 2015-09-30 | -$18.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | -$11.07M derived: sum of 2 quarters · filed 2016-11-08 | -$15.02M 10-Q · filed 2016-11-08 | -$68.11M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $7.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $3.12M 10-Q · filed 2016-08-08 | -$49.96M derived: sum of 3 quarters · filed 2017-02-27 | -$45.10M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | -$3.95M 10-Q · filed 2016-05-09 | -$57.04M derived: sum of 2 quarters · filed 2017-02-27 | -$52.17M derived: sum of 3 quarters · filed 2017-02-27 | -$42.91M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | -$53.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$48.22M derived: sum of 2 quarters · filed 2017-02-27 | -$38.96M derived: sum of 3 quarters · filed 2017-02-27 | -$39.98M 10-K · filed 2017-02-27 |
| 2014-09-30 | $4.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $14.13M derived: sum of 2 quarters · filed 2015-11-06 | $13.11M 10-Q · filed 2015-11-06 | |
| 2014-06-30 | $9.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $8.24M 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | -$1.02M 10-Q · filed 2015-05-08 | |||
| 2013-12-31 | -$3.47M 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $24.88M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |